Loss of exclusivityApril 2037latest FDA-listed patent expiry
CompanyIntraBio →See this company's full patent-cliff portfolio
Drug detail
Brand name
AQNEURSA
Active ingredient
LEVACETYLLEUCINE
Strength
1GM/PACKET
Dosage form
FOR SUSPENSION
Route
ORAL
Modality
Small molecule
FDA approval
September 2024
Marketing status
RX
Listed patents
Patent
Expires
Type
11400067
April 2037
use U-4170
12433862
April 2037
use U-4284
12433863
April 2037
use U-4285
Regulatory exclusivity
Code
Expires
ODE-498
September 2031
NCE
September 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.